UF Health Cancer Institute researchers will present a wide range of innovative cancer research at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, held May 29 to June 2 in Chicago.
The ASCO Annual Meeting is one of the most significant gathering of oncology professionals worldwide, allowing attendees to make connections and forging collaborations that can change the landscape of cancer care.
The meeting features state-of-the-art research, groundbreaking treatments and visionary insights. This year’s program features over 200 sessions and state-of-the-art science complementing Dr. Eric Small’s Presidential theme, “The Science and Practice of Translation: Improving Cancer Outcomes Worldwide.”
UF Health Cancer Institute members and UF faculty appear in bold below and trainees in italics.
Special Sessions
Highlights of the Year 1
May 31 | 8:45 – 9 a.m.
Highlights in Central Nervous System Tumors
Maryam Rahman
Oral Abstract Session
June 1 | 3 – 3:12 p.m.
Impact of access to effective post-progression therapies on survival outcomes in first-line randomized oncology trials
Co-authors: Daniel Araujo, Aline Fares
Rapid Oral Abstracts
May 29 | 2:57 – 3:03 p.m.
Support of academic non-clinical efforts for cancer investigator faculty at Association of American Cancer Institutes
Co-author: Thomas George
May 29 | 4:36 – 4:42 p.m.
Characteristics and survival of 4N and non-4N metastatic neuroblastoma across treatment eras: A report from the International Neuroblastoma Risk Group Task Force
Co-author: Arlene Naranjo
May 31 | 4:30 – 4:36 p.m.
Early results of COMPPARE, a prospective comparison of outcomes with proton and photon radiation in prostate cancer
Presenter: Nancy Mendenhall; Co-author: Curtis Bryant
Clinical Science Symposium
May 31 | 9:45 – 11:15 a.m.
Artificial intelligence (AI) in hematology and oncology fellowship (HOF) training: A multicenter survey of education, attitudes, and clinical use
Co-author: Jess Delaune
Poster Sessions
May 30 | 9 a.m. – noon
NRG-G1008: Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-NORTH AMERICA)
Co-author: Thomas George
NSABP FC-13 (EMPIRE): A phase II platform study of cemiplimab monotherapy or cemiplimab-based combinations in patients with colorectal cancer and minimal residual disease (MRD) after definitive therapy
Co-author: Thomas George
A randomized phase II/III trial of intraperitoneal paclitaxel plus systemic treatment vs systemic treatment alone in gastric carcinomatosis: STOPGAP II-ECOG0ACRUN EA2234
Co-author: Ibrahim Nassour
Risk-adapted step-up local therapy for malignant portal vein tumor thrombus from hepatic metastases: A real-world study of microwave ablation with and without iodine-125 seed implantation
Co-author: Shifali Bains
Precision Promise (PrP): Success rates of paired biopsies and biomarker testing results for metastatic pancreatic cancer (mPDAC) in a multi-center trial
Co-author: Thomas George
May 30 | 1:30 – 4:30 p.m.
Quantitative assessment of tumor shedding using AI-derived radiographic tumor burden and quantified liquid biopsy in advanced gastrointestinal cancers
Presenter: Abdul Qahar Yasinzai; Co-authors: Gahyun Gim, Meghan Ferrall-Fairbanks, Bruno Hochhegger, Ji-Hyun Lee, Thomas George
Race/ethnicity-stratified survival differences associated with psychotropic medication use in pancreatic cancer
Co-authors: Shuang Yang, Yi Guo, Diana Wilkie
June 1 | 9 a.m. – 12 p.m.
Risk of immune-related adverse events from checkpoint inhibitors in cancer patients with autoimmune disease: An emulated target trial
Co-author: Thomas George
Enhancing recruitment of AYAs with Hodgkin lymphoma through community partnerships: Prioritizing diverse populations
Co-authors: Carla Fisher, Leighton Elliott, Erin Mobley
Glucagon-like peptide-1 receptor agonist (GLP-1 RA) and hematologic cancer risk among older adults with type 2 diabetes
Presenter: Wei-Han Chen; Co-author: Thomas George
Empowering educators: An international virtual mentorship program for hematology/oncology medical educators
Co-authors: Shivang Danak, Martina Murphy
Impact of liquid biopsy training on real-world testing practices for advanced NSCLC across Latin America: The OMEGA (LACOG 0424/GBOT) survey
Co-author: Aline Fares
June 1 | 1:30 – 4 p.m.
Distinct prognosis roles of IDH mutation and high-risk genomic alterations in patients with primary chondrosarcoma
Co-authors: Elham Nasri
Evaluating satisfactory testing versus transcript grade performance between childhood cancer survivors and healthy controls
Co-authors: Daniel Indelicato, Julie Bradley, Carla Fisher, Nancy Mendenhall, Erin Mobley
TTFields with maintenance temozolomide (TMZ) and pembrolizumab versus TTFields with maintenance TMZ and placebo for newly diagnosed glioblastoma: The phase 3 EF-41/KEYNOTE D58 trial
Co-author: Ashley Ghiaseddin
Education Session
May 29 | 3:35 – 3:45 p.m.
Mirdametinib for Neurofibromatosis Type 1
Hans Shuhaiber
Publication Only
Social determinants of health (SDOH) and barriers to allogeneic hematopoietic stem cell transplantation (HCT) in acute myeloid leukemia (AML) in a community setting
Co-author: Marie Liu
Clinical outcomes with 14- vs 28-day monitoring after CAR-T therapy
Co-author: Chiranjeevi Sainatham
Impact of substance use disorder on pneumonia hospital outcomes in chronic lymphocytic leukemia: An inpatient nationwide analysis
First author: Oscar Borja Montes
Multichannel deep learning network for predicting survival in stage I NSCLC patients treated with SBRT
Co-author: Tithi Biswas
Knowledge and practice toward hereditary lung cancer in Brazil: A GBOT (Grupo Brasileiro de Oncologia Torácica) national survey
Co-author: Aline Fares
Activity of NP-G2-044 (fascin inhibitor) + anti–PD-1 in ICI-resistant advanced/metastatic solid tumors with expansion in cutaneous squamous cell carcinoma (CSCC)
Co-author: Thomas George
Clinical activity of immune checkpoint inhibitors in patients with advanced sarcomas: A retrospective single-center experience
First author: Oscar Borja Montes
